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Background: In an event of a smallpox outbreak in humans, the window for efficacious treatment by vaccination
with vaccinia viruses (VACV) is believed to be limited to the first few days post-exposure (p.e.). We recently
demonstrated in a mouse model for human smallpox, that active immunization 2–3 days p.e. with either
VACV-Lister or modified VACV Ankara (MVA) vaccines, can rescue animals from lethal challenge of ectromelia virus
(ECTV), the causative agent of mousepox. The present study was carried out in order to determine whether a single
dose of the anti-viral cidofovir (CDV), administered at different times and doses p.e. either alone or in conjunction
with active vaccination, can rescue ECTV infected mice.
Methods: Animals were infected intranasally with ECTV, treated on different days with various single CDV doses
and monitored for morbidity, mortality and humoral response. In addition, in order to determine the influence of
CDV on the immune response following vaccination, both the "clinical take”, IFN-gamma and IgG Ab levels in the
serum were evaluated as well as the ability of the mice to withstand a lethal challenge of ECTV. Finally the efficacy
of a combined treatment regime of CDV and vaccination p.e. was determined.
Results: A single p.e. CDV treatment is sufficient for protection depending on the initiation time and dose
(2.5 – 100 mg/kg) of treatment. Solid protection was achieved by a low dose (5 mg/kg) CDV treatment even if
given at day 6 p.e., approximately 4 days before death of the control infected untreated mice (mean time to death
(MTTD) 10.2). At the same time point complete protection was achieved by single treatment with higher doses of
CDV (25 or 100 mg/kg). Irrespective of treatment dose, all surviving animals developed a protective immune
response even when the CDV treatment was initiated one day p.e.. After seven days post treatment with the
highest dose (100 mg/kg), virus was still detected in some organs (e.g. lung and liver) yet all animals survived,
suggesting that efficacious single CDV treatment requires a potent immune system. The combination of CDV and
vaccination provided no additional protection over CDV alone. Yet, combining CDV and vaccination maintained
vaccination efficacy.
Conclusions: Altogether, our data substantiate the feasibility of single post-exposure antiviral treatment to face
orthopoxvirus infection.
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Smallpox, a human disease caused by variola virus
(VARV), was associated throughout the history with
pandemics involving profound illness and mortality. Fol-
lowing intensive worldwide vaccination campaign, the
World Health Organization (WHO) declared in 1980
that smallpox had been essentially eradicated [1,2]. The
success of this campaign led to cessation of vaccination
which in turn led to an increase in the percentage of un-
protected individuals. The growing concern of reemer-
gence of smallpox either accidentally or intentionally as
an agent of bioterrorism, highlight the need for evalu-
ation and approval of new countermeasures [3-5].
Smallpox disease is characterized by a relatively long
incubation period of 7–17 days which can provide in
principle attractive time-window for post-exposure (p.e.)
intervention before the onset of symptoms. Indeed, an-
ecdotal studies demonstrated the benefit of active vac-
cination with smallpox vaccine up to 4 days p.e. in
disease modulation and prevention of mortality [4]. Re-
cently, the feasibility of therapeutic p.e. vaccination was
reevaluated in various animal models for various lethal
orthopoxviruses using conventional and new generation
vaccines [6-8]. These studies highlighted the importance
of adequate animal models and a relevant virus which
could simulate the long incubation period in humans
and allow for the development of productive immune re-
sponse p.e.. Infection of mice with Ectromelia virus
(ECTV), the causative agent of the highly virulent and
contagious mousepox disease, is considered today as one
of the most relevant small animal models for smallpox.
This is mainly due to the facts that a) like VARV the
human pathogen, ECTV is a natural (rather than
adapted) mouse pathogen, b) it has a low respiratory (or
dermal) lethal dose (1–100 plaque forming units (pfu)),
c) the disease duration in the mouse (7–12 days) is
accelerated compared to human smallpox (18–22 days)
but still on a time scale that better simulates smallpox
disease in humans than other animal models, and d)
both viruses can be detected in respiratory gases during
pre-exanthem period and induce rash (although this is
route and strain dependent in mice) [7,9-12]. Yet, path-
ology in mousepox is associated with damage to the liver
and spleen but relatively less in human smallpox.
In a p.e. scenario, anti-virals (antibodies or drugs such
as IVIG, CDV, ST-246) have two major advantages over
vaccines: a) they provide immediate protection, and b)
their direct mechanism of action is not essentially
dependent on an effective immune system. On the other
hand, in many cases repeated treatments are required to
achieve protection [13], resistant viruses tend to emerge
[14] and treatment can potentially impede the immune
response [15]. On the background of immune deficiency
or in cases of highly virulent strains exhibiting strongimmune evasion properties (e.g. ECTV-IL-4) repeated
treatments and combination of drugs are required to
achieve protection [16,17].
Cidofovir (CDV), a nucleoside analogue is an anti-viral
drug used for treatment of CMV retinitis in acquired
immune deficient syndrome (AIDS) patients. The
human recommended dose is 5 mg/kg applied intraven-
ously. The administration regimen is once a week during
the first two weeks followed by one dose every other
week. The drug is administered together with probene-
cid, a uricosuric agent, to reduce renal toxicity. Beside
CMV treatment, CDV was also found to be highly effica-
cious against dsDNA viruses including herpesviruses,
papillomaviruses and poxviruses [18]. CDV was found to
be effective in several poxvirus diseases in various ani-
mal models [19-23] and it is approved for the treatment
of adverse reactions in individuals that were either vacci-
nated or accidentally exposed to smallpox-vaccine [24].
Currently, CDV is approved for human use only in its
intravenous formulation. New forms of the drug like
CMX001 (hexadecyloxypropyl ester, HDP-CDV, an oral
form of CDV) were developed exhibiting improved bio-
availability and reduced toxicity [25-27]. These new
CDV derivatives and antivirals like ST-246 were evalu-
ated for p.e. treatment in several animal models [28-32].
In mouse models, the effectiveness of CDV and its deri-
vatives was evaluated against various orthopoxviruses in-
cluding VACV-WR, cowpox, monkeypox and ECTV
infections [13,23,29,30,33-37]. Recently, the combination
of CMX001 and ST-246 demonstrated to be effective in
treatment of recombinant ECTV-IL4 infection of mice, a
disease that is uncontrolled by vaccination or single drug
treatment [16]. There is a concern that this information
will be used to generate a recombinant VARV-IL4 that
would also break the immunity conferred by the vaccine.
Based on the similarities between mousepox and small-
pox, it is possible that the combination of highly effect-
ive drugs and/or the use of VARV based vaccine would
prove efficacious [16].
In the majority of the studies the drugs were repeat-
edly administered for several days or given at doses
higher than the recommended human dose. In a case of
bioterrorism attack there is a need for an antiviral treat-
ment that will be simple, cost effective, short and if pos-
sible involving a single administration.
The purposes of the present study were: a) to evalu-
ate the therapeutic efficacy of a single p.e. CDV treat-
ment against lethal ECTV infection, b) to evaluate the
effect of the CDV treatment on the induction of pro-
tective immunity in ECTV infected as well as in naïve
non-exposed but vaccinated mice, and c) to examine
possible advantage for a combined treatment (active
vaccination given in conjunction with CDV) in a p.e.
scenario.
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meters of absorption, distribution and elimination of
CDV in mice, the human equivalent dose for mice was
estimated to be based on weight only. Alternatively, allo-
metric conversion based on body surface area revealed
60 mg/kg as the human equivalent in mice [38]. We
show that single treatment with CDV at a dose equiva-
lent to the recommended human dose based on weight
(5 mg/kg) conferred solid p.e. protection even if admi-
nistered four days p.e.. A higher dose (100 mg/kg) which
is close to the dose given to humans based on the
allometric conversion, protected even if administered 6–
7 days p.e., a few days before death. Importantly, protec-
tive immunity developed in all surviving mice regardless
of the treatment dose or timing. We further demonstrate
that CDV treatment can be accompanied by concomi-
tant vaccination without impeding treatment efficacy.
The studies demonstrate that with an appropriate anti-
viral drug, the reemergence of smallpox infection may
be treated successfully even by single treatment at rela-
tively late stages p.e..
Results and discussion
Post-exposure treatment with a single dose of cidofovir
In order to evaluate the efficacy of single dose treatment,
an established mouse model of ECTV infection was used
[7]. BALB/c mice were infected with ECTV by intranasal
instillation (at least 15 LD50, 1 pfu = 1 LD50) and treated
with a single dose of 2.5, 5, 10, 25, 50 and 100 mg/kg
CDV on various days p.e. (Table 1, Figure 1). Control
infected untreated mice lost about 15% of their initial
weight starting at day 6 and succumbed to disease with
a mean time to death (MTTD) of 10.2 ±1.6. Moribund
mice lost weight and exhibited ruffled fur. Improvement
in the status of morbidity (based on weight loss) and
mortality in the treated groups were dose and time




2.5 50 (6) 100 (6)* 83 (6)*
5 83 (12)* 92 (12)* 91 (22)*
10 N.D. 100 (6)* 100 (6)*
25 100 (6)* 100 (6)* 100 (12)*
50 100 (6)* 100 (6)* 100 (6)*
100 100 (6)* 100 (6)* 100 (6)*
a A single dose of cidofovir was given at days 1–7 post intranasal challenge with EC
succumbed to infection.
b The numbers indicate percent survival in each group. The number of animals in e
each group. Large groups contained 12 animals (2 experiments of 6 animals), 22 an
and 28 animals (3 experiments of 6 animals plus additional experiment with 10 ani
* Indicates for statistical significance compared to the control infected untreated gron day 1 p.e. protected 50% of the animals (P = 0.18 rela-
tive to the control infected untreated group). The most
effective protection was achieved when CDV was admi-
nistered on day 2, 3 and 4 p.e. (100%, 83% and 64%
P= 0.02, 0.015 and 0.001 compared to the control
infected untreated group, respectively). One third of the
animals survived when treated on the 5th and 6th day
(P = 0.07 and 0.45 for days 5 and 6 respectively). All ani-
mals treated with the dose of 2.5 mg/kg lost weight and
exhibited other signs of illness similarly to untreated
animals and recovery was observed starting on days 11–
13 p.e. (Figure 1A). Application of CDV at 5 mg/kg
(equivalent to the human recommended dose based on
weight) improved survival rates providing solid protec-
tion up to 4 days p.e. (68%) and allowing 55% survival
when treatment was administered at day 5 or 6 p.e.
(Table 1, P = 0.002, 0.0003, <0.0001, <0.0001, 0.004,
0.004 for days 1–6 respectively). Morbidity was observed
in all treated animals; yet increasing the treatment dose
from 2.5 to 5 mg/kg was associated with reduced weight
loss and shortening the time to recovery by 1–2 days
(Figure 1B). A single dose of 10 mg/kg conferred full
protection on all days examined (days 2–4; Table 1,
P = 0.002 in all cases of 10 mg/kg). Animals treated
2 days p.e. did not exhibit signs of illness. Yet, slight
morbidity (<10% weight loss) was observed in mice
treated 3–4 days p.e. (Figure 1C). Increasing the dose to
25, 50 and 100 mg/kg further improved both survival
and morbidity. At 25 mg/kg, full protection was
achieved when treatment commenced up to 3 days p.e.
and only sporadic mortalities were observed if treatment
was applied later (1 out of 12 and 1 out of 6 from the
groups treated on days 4 and 5 respectively (Table 1,
P = 0.015, 0.015, <0.0001, 0.0003, 0.015, 0.002 for days
1–6 respectively relative to the control infected
untreated group)). Morbidity was apparent only in the
groups treated on day 5 and 6 (Figure 1D). 50 mg/kglethal ECTV infection in a dose and time
Dayb
4 5 6 7
64 (28)* 32 (22) 33 (6) N.D.
68 (28)* 55 (22)* 55 (22)* N.D.
100 (6)* N.D. N.D. N.D.
92 (12)* 83 (6)* 100 (6)* N.D.
100 (6)* N.D. N.D. N.D.
100 (6)* 100 (6)* 100 (6)* 50 (6)
TV. 29 out of the 30 control infected untreated mice used in this experiments
ach group is indicated in parentheses. A minimum of 6 animals were used in
imals (2 experiments of 6 animals plus additional experiment with 10 animals)
mals). N.D. – not done.
oup that was used in the same experiments (Fisher's Exact test, P< 0.05).
Figure 1 Single dose of cidofovir post ECTV challenge confer protection in a time and dose dependent manner. Mice were challenged
by intranasal instillation with a 15–100 pfu = 15–100 LD50 of ECTV. A single dose of cidofovir was given at various days p.e. A: 2.5 mg/kg,
B: 5 mg/kg, C: 10 mg/kg, D: 25 mg/kg, E: 50 mg/kg, F: 100 mg/kg. Weight loss was determined every 1–3 days. Means ± standard errors of
percent of the initial body weights are presented. The control infected untreated group is a representative group (n = 6) from one of the
experiments. Similar death profile was observed in all the other experiments. Numbers of animals in each group are indicated in Table 1.
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tion preventing any signs of morbidity (Table 1,
P = 0.015 relative to the control infected untreated
group, Figure 1E). At the highest CDV dose of 100 mg/
kg all the animals were protected when treatment com-
menced up to day 6 and 50% protection was achieved
when treatment was given on day 7 (Table 1, days 1–6
P= 0.015, day 7 P = 0.54). Morbidity was observed only
in groups treated on days 6 and 7 (Figure 1F).
Several studies reported on the efficacy of repeated
treatments with CDV or CMX001 against different
orthopoxviruses [12,23,29,30]. Both drugs protected A/
Ncr mice from lethal mousepox disease when given onday 0 and 3 p.e. [13]. A single dose of 100 mg/kg
CDV was previously shown to confer protection to
BALB/c mice exposed to a lethal VACV-WR or cow-
pox virus challenge when given up to 3 days p.e.
[35,37]. However; a single dose of CMX001 (25 mg/
kg) was sufficient to protect A/Ncr mice from lethal
mousepox (20 pfu) even when administered 4–5 days
p.e. [34]. Taken together, the present and previous
studies, in which mice were infected with the natural
poxvirus in mice (ECTV), provide clear evidence that
treatment at very late stages of the disease can be effi-
cacious even with a single dose administration of CDV
or CMX001.
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be efficacious in protection of mice from ECTV airway
(intranasal) infection. A dose of 5 mg/kg, efficiently
protects mice even when applied 6 days p.e. while
increasing the dose up to 100 mg/kg fully protected at
day 6 p.e. and 50% at day 7 p.e., a time when the animals
were already at progressive stages of the disease and about
4 days before death of the infected untreated group.
At low CDV doses (2.5-5 mg/kg), optimal protection
was achieved when single treatment was given on days 2
or 3 p.e. while treatment on day 1 p.e. was less protect-
ive. Unlike protocols of repeated injections, in a single
dose treatment of CDV the levels of the drug in the cir-
culation are expected to decline significantly within 24
hours [39]. Since CDV inhibits DNA replication, it tar-
gets only viral particles which are in their DNA replica-
tion state. As a consequence, unaffected viral genomes
may resume replication when drug levels are very low,
which could lead eventually to morbidity and death. We
believe that this phenomenon can also account for the
observation of Parker et al. [13] that a CDV treatment
(100 mg/kg) starting 3 days p.e. was better than an earl-
ier treatment starting on the day of virus exposure.
CDV protection following ECTV infection and
development of immune response
The observation that a single injection of CDV could be
sufficient to provide protection in mice, led us to exam-
ine a possible contribution of the immune response inFigure 2 Low dose of CDV treatment does not impair the developme
Development of specific orthopoxvirus antibodies (IgG) in sera of CDV trea
were infected intranasal with ECTV (35–60 pfu = 35–60 LD50). Single CDV tr
Sera of infected, untreated mice were collected from convalescent mice th
0.1-1 pfu = 0.1-1 LD50). Titer in GMT, error bars: Geometric standard deviatio
versus 10–100 mg/kg treated groups. * Indicates for statistical significancethe recovery of the CDV treated animals. We first deter-
mined the development of the humoral immune re-
sponse in mice surviving a sub-lethal (0.1-1 pfu = 0.1-1
LD50) ECTV challenge without CDV treatment and
found that the specific orthopoxvirus IgG titers were
32,250 (GMT) 30 days post infection (Figure 2, low CD,
left bar). A low dose (2.5 and 5 mg/kg) of CDV treat-
ment administered up to 4 days following infection with
a lethal ECTV dose (35–60 pfu = 35–60 LD50) resulted
in a reduction in antibody titer (average of 19,050 GMT,
P = 0.08). However, increasing the dose to 10–100 mg/kg
resulted in a significant reduction in the IgG titer (an
average of 3,140 GMT) (Figure 2; P = 0.007 for the low
CD control group and P< 0.0001 for the groups treated
with 2.5-5 mg/kg compared to the 10, 25, 50 and
100 mg/kg treated groups). Higher antibody titers corre-
lated with disease severity (Figure 3, R2 = 0.77) most
likely reflecting viral antigen accumulation in moribund
animals that were treated with a low dose (2.5 or 5 mg/
kg) or high dose at late stage of the infection (i.e.
100 mg/kg at day 6–7 p.e.).
Interestingly, development of vaccinia virus specific
antibody response was detected even when animals were
treated soon after infection (24 hr p.e) and with the
highest dose (100 mg/kg) of CDV. Thus although the in-
fectious dose was relatively low (<100 pfu) the drastic
antiviral treatment did not abolish propagation of virus
to an extent that is sufficient for prevention of induction
of immune response.nt of humoral immune response in surviving ECTV infected mice.
ted convalescent mice was determined by ELISA 30 days p.e.. Mice
eatment with 2.5-100 mg/kg was given on the indicated days.
at were infected with a low challenge dose (low CD, left bar,
n. Dotted line represents the average IgG titer of the 2.5-5 mg/kg
(t-test, P< 0.01).
Figure 3 Development of antibody response correlated with
morbidity in CDV treated, ECTV infected mice. The average of
the weight loss of each group was correlated to the average IgG
ELISA GMT (geometric mean titer). 2.5, 5 and 50 mg/kg days
1–4, 10 mg/kg days 2–4, 25 mg/kg days 1–6, 100 mg/kg days 1–7.
n = 3-9 in each group.
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CDV treatment, we evaluated the effect of CDV based
on another hallmark of the disease - viral load in
target organs. To this end, mice were intranasally (i.n.)
infected with ECTV (20 pfu = 20 LD50) and viral loads
were determined on days 1, 2, 8 p.e. in lungs and on
day 8 p.e. in lungs, liver, spleen and blood (Figure 4).
The viral load present at the time of CDV treatment
(24 hours p.e.) was 120 pfu/lung (n = 4; Figure 4A). The
effect of CDV treatment was examined on day 2 and
8 p.e.. On day 2, the 2.5 mg/kg treatment reduced
the average viral load by 17.5% (to 4.1X103 pfu/lung,
P = 0.25) while the 100 mg/kg treatment significantly
reduced the viral load by 82% (to 5.8X102 pfu/lung;
Figure 4A, P = 0.05). When viral load in the target organs
was determined 8 days p.e., long after CDV was cleared
from the circulation, a significant reduction in the viral
load was observed (100 mg/kg compared to infected un-
treated, P = 0.05) but viral particles were still detected in
the lungs and the liver (Figure 4). Nevertheless, all ani-
mals in this group and 55 percent of animals in the
2.5 mg/kg treatment group survived the infection. It is
worth mentioning in this context, that previously it was
demonstrated that CDV treatment in immunodeficient
mice was effective only during drug treatment periods
[40,41]. We may therefore conclude that an active and
potent immune system is required for complete recovery
from pox disease following the single CDV treatment.
To further elucidate the effect of CDV on the extent
of protective immunity against ECTV, surviving animals
treated with the lowest (2.5 mg/kg) or highest (100 mg/
kg) dose were re-challenged 45 days after the initial in-
fection. All animals, irrespective of their treatment his-
tory (i.e. time of initiation of treatment: 1–6 days p.e), orthe dose used and regardless of their antibody titers
were fully protected and did not exhibit any signs of ill-
ness. Overall, our results suggest that the protective
CDV treatment during poxvirus infection does not pre-
vent the development of protective immunity.
Combined treatment of CDV and vaccination
In a case of smallpox outbreak, ring vaccination is
recommended to treat those already exposed and to pro-
tect unexposed individuals [42]. Since CDV can inhibit
replication of both the virulent and the vaccine strain, a
potential consequence of the CDV treatment might be
interference with the development of immune response
following vaccination. To test this possible interference,
we treated naïve mice with CDV at concentrations of 5,
25 or 100 mg/kg and then immunized them after 4 or
24 hours with 1X106 pfu of VACV-Lister by tail scarifi-
cation. The extent of the immune response following
this treatment regime was evaluated by: 1) scoring the
"clinical take", 2) measuring level of serum IFN-gamma,
3) determining the level of orthopox-specific antibodies,
and 4) investigating the ability of treated animals to
withstand a lethal ECTV challenge.
Both "clinical take" scores and IgG antibody levels
indicated that CDV treatment did not interfere with vac-
cination efficacy (P> 0.05 compared to the control vac-
cinated without CDV treatment). The major reduction
in the "clinical take" score was observed when 100 mg/
kg CDV was given 4 hours before vaccination (Figure 5;
Table 2, P = 0.06). When the same dose (100 mg/kg) was
applied 24 hours before vaccination no reduction in
"clinical take" score was noted (Figure 5; Table 2,
P = 1.0). In all cases secretion of IFN-gamma was not
inhibited by CDV, further indicating that CDV treatment
did not interfere with vaccination efficacy. In certain
treatments IFN-gamma levels were significantly higher
than the control group (Table 2). Finally, all animals,
treated with the combined treatment of CDV and vac-
cination, were fully protected from a lethal ECTV chal-
lenge (70 pfu = 70 LD50) given 31 days post treatment,
with no signs of illness in contrast to mice treated with
CDV alone (Figure 6). Only one animal out of 36 tested,
that was treated with 100 mg/kg CDV 4 hours prior to
vaccination, developed reduced immune response (poor
"clinical take" (Figure 5 plate I) and lower level of IFN-
gamma in the serum (5 pg/ml) which was comparable to
the level of IFN-gamma of a naïve unvaccinated animal
(3 pg/ml)). Only this animal exhibited weight loss fol-
lowing the challenge but eventually, regained weight and
survived.
Published data regarding the effect of CDV on vaccin-
ation of naïve animals varied between different animal
models. While CDV interfered with Dryvax elicited im-
mune response in cynomolgus monkeys after monkeypox
Figure 4 CDV drug treatment reduced the viral titers in various organs following ECTV infection. Mice were infected with 20 pfu i.n.
(= 20 LD50) and treated with 2.5 or 100 mg/kg CDV 24 hours later. Viral titers were evaluated in lungs on days 1 and 2 p.e. (A) and on day 8 p.e.
in lungs (B), liver (C), spleen (D) and blood (E). Dotted line indicates the limit of detection. * Indicates for statistical significance compared to the
control unprotected without CDV treatment (Mann–Whitney U-test, P< 0.05).
Israely et al. Virology Journal 2012, 9:119 Page 7 of 12
http://www.virologyj.com/content/9/1/119challenge [15], Bray and colleagues could show that vac-
cination efficacy was not affected by co-administration of
CDV in a mouse model of cowpox infection [33]. By
combining CDV treatment and vaccination of naïve ani-
mals, we were able to demonstrate in this work that the
development of protective immune response was essen-
tially unaffected by CDV treatment even if CDV was
given at high dose 4 hours prior to the vaccination. In all
of the immunological parameters examined ("clinical
take", IgG titer and IFN-gamma) the effect of the drugwas minor, and even in cases where minor effects
were observed the ability to control ECTV challenge
was not hampered. These observations could be of
major significance regarding the first days after an ex-
posure event, when the infection status is unclear and
anti-viral treatment has already been initiated in the
population.
In view of these encouraging results we evaluated the
protective efficacy of a combined treatment of CDV and
vaccination in combating lethal ECTV infection. In a
Table 2 Single CDV treatment in conjunction with VACV vaccination does not impair the development of protective
immunity
Cidofovir (mg/kg)a Vaccination post CDV (day) "Clinical take" scoreb IFN-gamma (pg/ml)c IgG antibodies (GMT)d
5 0 3.0 ± 0 129 ± 12* 2540
1 3.0 ± 0 136 ± 48 3200
25 0 2.8 ± 0.2 151 ± 24* 5080
1 2.8 ± 0.2 185 ± 34* 2540
100 0 2.2 ± 0.4 105 ± 72 2540
1 3.0 ± 0 413 ± 131 4032
Controle N.D. 3.0 ± 0 55 ± 20 4525
naïvesf N.D. N.R. 3 ± 2 <100
a Mice were CDV treated at day 0 (4 hours) or day 1 (24 hours) prior to vaccination with VACV-Lister by tail scarification.
b The "clinical take" score refers to the size and appearance of the tail lesion at the site of vaccination. The score was determined 13 days post vaccination
(n = 6/group, mean± SE).
c IFN-gamma was examined in mice sera 7 days post vaccination (n = 3/group, mean ± SE).
d Antibody titers in mice sera were determined at day 31 post vaccination (n = 3/group, GMT – geometric mean titer).
e Control – vaccination without CDV treatment.
fNaives – no treatment.
* Indicates for statistical significance compared to the control vaccinated without CDV treatment (t-test, P< 0.05). N.D. – not done. N.R. – not relevant.
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MVA confer protection against relatively low ECTV
challenged dose (3 LD50) even when given 2–3 days p.e.
[7]. As different mechanisms and time scales are
involved in antiviral therapy and active vaccination, it
was therefore tempting to determine whether or not a
combined treatment could have been beneficial over the
individual treatment. To test this hypothesis, mice were
exposed to a high lethal dose of ECTV (70–100 pfu =
70–100 LD50) and treated with a single dose of 5 mg/kg
CDV on days 3, 4 or 5 p.e.. As indicated in Table 3 cer-
tain CDV treated groups were also vaccinated with
VACV-Lister (tail scarification, 1X106 pfu) or MVA
(intramuscularly (i.m.), 1X108 pfu) 4 hours after CDVFigure 5 Single CDV treatment in conjunction with VACV vaccination
treated with CDV at concentrations of 5, 25 or 100 mg/kg 4 hours (day 0) o
was conducted by tail scarification on the base of the tail with 1X106 pfu. A
prior to vaccination with 5 mg/kg (A-C), 25 mg/kg (D-F), 100 mg/kg (G-I). M
and control animals vaccinated without CDV treatment (M-O). Each group
animal from plate I was the only one with the low score of 1.treatment. Treatment with CDV alone or combined with
vaccination afforded significant protection when given
up to 4 days p.e.. Yet, the addition of vaccination did not
significantly change survival rates or mean time to death
(MTTD) over the protection achieved by CDV alone
(Table 3, P> 0.05 when CDV is compared to CDV with
vaccinations in each time point, Fisher's exact test). Post-
ponement of vaccination to 24 hours post CDV treat-
ment, as well as changing the order of treatment,
(namely first administration of the vaccination and 4
hours later CDV) showed similar results (data not
shown). Nevertheless, the combined treatment of CDV
and vaccination maintained treatment efficacy of CDV
and can potentially provide long-term immunity.does not impair the development of a “clinical take”. Mice were
r 24 hours (day 1) prior to vaccination with VACV-Lister. Vaccination
nimals` "clinical take" was examined at day 13. Mice treated 4 hours
ice treated with 100 mg/kg CDV 24 hours prior to vaccination (J-L)
contained 6 mice from which 3 representatives are shown. Note that
Figure 6 Single CDV treatment in conjunction with VACV vaccination does not impair the development of protective immunity. Mice
were treated with single dose of 5, 25 or 100 mg/kg of cidofovir at day 0 (4 hours) or day 1 (24 hours) prior to vaccination with VACV-Lister by
tail scarification (1X106 pfu). One group received only CDV (CDV 100 mg/kg control). 31 days post treatment mice were challenged i.n. with
70 pfu = 70 LD50 of ECTV. Morbidity (percent of initial weight ± SE) of each group is presented.
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In this work, we demonstrated that a single CDV treat-
ment can be used as a p.e. treatment to rescue mice
from lethal orthopoxvirus infection. Based on the pro-
tection rates achieved with a single administration of
CDV in the ECTV mouse model, it is reasonable to sug-
gest that the time window for the treatment of humans
will be similar or even prolonged allowing additional
time for preparedness in cases of reemergence of small-
pox. To ensure efficient disease containment with min-
imal number of treatments, our data clearly suggests
that a single antiviral treatment might be sufficiently
protective.
Due to the nature of smallpox disease and the rela-
tively long incubation time from infection until the ap-
pearance of the first specific symptoms, a smallpoxTable 3 Cidofovir and vaccination combined treatment
post ECTV challenge
Treatmenta Day of treatment Survival (%) MTTD
CDV 3 100* N.R.
CDV+ VACV-Lister 90* 17
CDV+MVA 100* N.R.
CDV 4 80* 14
CDV+ VACV-Lister 50* 10.3
CDV+MVA 50* 11.6
CDV 5 30 11.3
CDV+ VACV-Lister 40 12.8
CDV+MVA 40 13
Infected untreated N.R. 0 10.3
a Vaccinations 4 hours after CDV (5 mg/kg) were done using tail scarification
with VACV-Lister (1X106 pfu) or MVA i.m. (1X108 pfu) at days 3, 4 or 5 after
animals were challenged i.n. with 70–100 pfu = 70–100 LD50 of ECTV. N = 10 in
each group. N.R. – not relevant. * Refers to a statistically significant difference
from the control infected untreated (Fisher's Exact test, P< 0.05).outbreak will probably comprise a large spectrum of
individuals from non-infected thorough asymptomatic to
symptomatic infected persons. Because our data suggests
that combination of CDV and vaccination does not im-
pair the immune response induced by the vaccine it is
possible that the addition of CDV might be advanta-




ECTV strain Moscow (ATCC VR-1374), VACV-Lister
(Elstree; provided by the Israeli Ministry of Health) and
MVA clonal isolate F6 at the 584th CEF passage were
propagated and titrated as described previously [7].
Briefly, ECTV Moscow was propagated in HeLa (ATCC-
CCL-2) cells and titrated on BSC-1 cells (ATCC-CCL-
26). VACV-Lister was propagated on the chorioalantoic
membranes of embrionated eggs and titrated on Vero
(ATCC-CCL-81) cells. MVA was propagated in second-
ary chicken embryo fibroblasts and titrated on BHK-21
(ATCC-CCL-10) cells.
Challenge experiments
Female BALB/c mice (6–8 weeks old) were purchased
from Charles River Laboratories, UK. For i.n. challenge,
mice were anesthetized (Ketamine 75 mg/kg, Xylazine
7.5 mg/kg in PBS) and ECTV (20 μl) was administered
to the nostrils [43]. Mice were challenged with at least
15 ECTV LD50 (1 pfu = 1 LD50). An untreated and
infected untreated groups served in all experiments as
controls. CDV was diluted freshly for each treatment
day with PBS and kept at room temperature until ad-
ministration by intraperitoneal (i.p.) injection (0.1 ml,
single dose in all cases). In certain groups, results of
repeated experiments were merged together as described
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1–3 days. Rechallenge experiment was done in treated
animals 45 days after the first challenge. General proce-
dures for animal care and housing were done in compli-
ance with the regulations for animal experiments at the
Israel Institute for Biological Research.
Determination of IgG ELISA titer
Vaccinia specific IgG ELISA titer was determined in
mice sera by ELISA as described elsewhere [44]. Briefly,
96-well microtiter plates were coated with 50 μl of β-
propiolactone inactivated crude vaccinia antigen (IHDJ
strain, equivalent to 2 × 106 pfu). After blocking, the
plates were incubated for 60 min with two-fold serial
serum dilutions and then subsequently incubated with
alkaline phosphatase conjugated goat anti-mouse IgG
(1:1000, Sigma–Aldrich). P-nitrophenyl phosphate sub-
strate was added and the optical density was measured
(Spectramax 190 microplate reader, Molecular Devices,
Sunnyvale, CA) after 60 min. IgG end-point titers were
defined as the reciprocal serum dilutions giving twice
the average optical density values obtained with bovine
serum albumin.
Determination of viral load in mouse organs
Blood samples were collected from the tail vein. Then
the animals were anesthetized, perfused and sacrificed.
Organs were transferred immediately to liquid nitrogen
and stored at −70 °C. Tissues were homogenized
(ULTRA-TURAXW IKA R104) for 30 sec in ice cold PBS
(spleens and lungs in 1.5 ml, livers in 4 ml). Following
homogenization, the materials were sonicated (3X, 30 s)
centrifuged (270 X gravity, 10 min, 40 C) and superna-
tants were collected for virus titration. Titration of ECTV
was performed on 100% confluent monolayers of BSC-1
cells (ATCC # CCL26) in 12 well tissue culture grade
plates (Nunc). Samples were serially diluted in virus dilu-
tion medium (MEM containing 2% fetal calf serum and
supplemented with L-glutamine, non-essential amino-
acids solution and penicillin-streptomycin solution (Bio-
logical Industries, Israel)). Culture media was aspirated
from the cell monolayers and a 0.2 ml sample of each
virus dilution was transferred to each well in triplicates.
The virus was allowed to adsorb for 1 hour at 37 °C on a
reciprocal rocker, and then the cell monolayers were
overlaid with 2 ml of methylcellulose based overlay
(5%W/V methyl cellulose (Sigma)) sterilized by autoclav-
ing and formulated in virus dilution medium supplemen-
ted with 0.15% sodium bicarbonate (Biological Industries
Israel). The infected cultures were incubated uninter-
rupted at 37 °C in a 5% CO2 incubator. After 5 days the
overlay was aspirated and the monolayers were fixed-
stained for 5 minutes at room temperature with a crystal
violet solution (0.1%W/V crystal violet (Merk) in 20%Ethanol). Then the stain was aspirated and the wells were
washed with tap-water, dried and plaques were counted.
Combined cidofovir and VACV-Lister vaccination
Naïve mice were treated with 5, 25 or 100 mg/kg CDV
(0.1 ml, i.p.) and vaccinated intradermally (i.d.) by tail
scarification 4 or 24 hours later with VACV-Lister
(1X106 pfu in 10 μl of PBS + 2%FCS, [44]). This dose is
equivalent to 2.5X105 pock forming units which corre-
lates to the human vaccination dose (2X105 pock form-
ing units).
"Clinical take" evaluation
"Clinical take" evaluation was performed as described else-
where [44]. Briefly, the "clinical take", referring to the size
and appearance of the tail lesion at the site of vaccination,
was scored from 0 (no "clinical take") to 3 (full extended
scab developed at the site of vaccination) 13 days after vac-
cination. The average score of each group (n= 6) was
determined.
IFN-gamma assay
IFN-gamma concentration in the serum was measured
using QuantikineW mouse IFN-gamma Immunoassay kit
according to the manufacturer's instructions (R&D Sys-
tems, MN). Briefly, samples, standards and control were
added to a pre-coated microplate containing monoclonal
antibody specific for mouse IFN-gamma and an enzyme-
linked polyclonal antibody specific for mouse IFN-
gamma was added. After adding the substrate solution
the reaction was stopped and the color intensity was
measured by SunriseTM Remote ELISA reader (TECAN,
Austria). Sample values were then read off the standard
curve.
CDV and vaccination post ECTV challenge
Animals were first exposed to ECTV (15 i.n. pfu = 15 i.n.
LD50) and then treated with CDV (5 mg/kg) on days 3, 4
or 5 p.e., respectively. Four or 24 hours following the
CDV treatment mice were vaccinated with VACV-Lister
(i.d. - 1X106 pfu in 10 μl) or with MVA (i.m. - 1X108 pfu
in 50 μl) or left unvaccinated.
Statistical analysis
Fisher's exact test was used to compare survival rates be-
tween groups. Two tailed, unpaired Student t-test was
used for comparisons between groups regarding the
IFN-gamma and IgG antibodies levels data. The
Freeman-Halton extension of the Fisher exact probabil-
ity test was used to compare "clinical take" scores. The
non-parametric Mann–Whitney U-test was used to
compare viral loads (one tailed). In all cases, P< 0.05
indicates a significant difference.
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